| Title : Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's disease - Cutler_1992_J.Geriatr.Psychiatry.Neurol_5_192 |
| Author(s) : Cutler NR , Sramek JJ , Murphy MF , Nash RJ |
| Ref : J Geriatr Psychiatry Neurol , 5 :192 , 1992 |
| Abstract : |
| PubMedSearch : Cutler_1992_J.Geriatr.Psychiatry.Neurol_5_192 |
| PubMedID: 1418362 |
| Title : Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease - Cutler_1992_Ann.Pharmacother_26_1118 |
| Author(s) : Cutler NR , Sramek JJ , Murphy MF , Nash RJ |
| Ref : Annals of Pharmacotherapy , 26 :1118 , 1992 |
| Abstract : |
| PubMedSearch : Cutler_1992_Ann.Pharmacother_26_1118 |
| PubMedID: 1421679 |
| Title : Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease - Murphy_1991_Ann.N.Y.Acad.Sci_640_253 |
| Author(s) : Murphy MF , Hardiman ST , Nash RJ , Huff FJ , Demkovich JJ , Dobson C , Knappe UE |
| Ref : Annals of the New York Academy of Sciences , 640 :253 , 1991 |
| Abstract : |
| PubMedSearch : Murphy_1991_Ann.N.Y.Acad.Sci_640_253 |
| PubMedID: 1776747 |
| Title : Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings - Cutler_1990_J.Clin.Pharmacol_30_556 |
| Author(s) : Cutler NR , Murphy MF , Nash RJ , Prior PL , De Luna DM |
| Ref : Journal of Clinical Pharmacology , 30 :556 , 1990 |
| Abstract : |
| PubMedSearch : Cutler_1990_J.Clin.Pharmacol_30_556 |
| PubMedID: 2355106 |